Not Every White Patch Is Vitiligo: How Clinicians Separate True Depigmentation From Its Four Most Common Mimics

A light patch on the skin triggers one question more than any other in pigmentation clinics: is this vitiligo? The answer matters because vitiligo is an autoimmune disease with its own treatment ladder, while its mimics are usually self-limited or infection-driven. Getting the label wrong can mean months of unnecessary topical steroids, or worse, missed early vitiligo during the window when repigmentation therapy works best.

The core distinction is hypopigmentation versus depigmentation. In hypopigmented conditions, melanocytes are still present but underperforming: they make less melanin or transfer it poorly to surrounding keratinocytes. In vitiligo, melanocytes are progressively destroyed by a CD8 T cell response directed at melanocyte antigens, so the patch eventually contains few or no pigment-producing cells at all. That biological difference is what a Wood's lamp exploits. Under 365 nanometer ultraviolet light, fully depigmented skin fluoresces a bright, chalky blue-white because there is no melanin left to absorb the UV. Partially pigmented mimics look only faintly lighter, without that sharp accentuation. It is a two-minute test, and it is often the single most useful step in the workup.

Pityriasis alba is the most common mimic in children and teens, particularly those with an atopic background. It appears as ill-defined, slightly scaly, round patches on the cheeks and upper arms. The mechanism is low-grade eczematous inflammation that disrupts melanosome transfer from melanocytes to keratinocytes. The melanocytes survive, which is why the borders are fuzzy rather than sharply demarcated, and why the patches fade over months once the skin barrier calms down. Vitiligo, by contrast, tends to have crisp, convex borders and no scale. If a lesion is scaly and blurry-edged in a child with dry skin, pityriasis alba should lead the differential.

Tinea versicolor, caused by overgrowth of Malassezia yeast, produces hypopigmented, finely scaling macules that favor the chest, back, and shoulders, especially after heat and sweating. The yeast produces azelaic acid, which directly inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis. Pigment production drops in affected zones even though melanocytes remain intact. Two clues separate it from vitiligo: gentle scraping raises a fine scale, and potassium hydroxide microscopy shows the classic yeast and short hyphae pattern. Antifungal therapy clears the organism, though the pigment can take weeks to normalize because melanin recovery lags behind the infection.

Post-inflammatory hypopigmentation follows almost any skin insult: eczema flares, psoriasis plaques, burns, resurfacing procedures, or aggressive cryotherapy. Inflammation temporarily suppresses melanocyte function or damages a portion of the melanocyte population. The tell is history and geometry: the light area maps precisely onto where the prior rash, injury, or procedure occurred. Most cases recover over three to twelve months as melanocytes repopulate from the follicular reservoir. The caveat clinicians watch for is that trauma can also trigger vitiligo in predisposed individuals through the Koebner phenomenon, in which new vitiligo lesions arise at sites of friction or injury. A post-procedure white patch that keeps expanding beyond the original injury footprint, or turns bright under Wood's lamp, deserves reassessment.

Idiopathic guttate hypomelanosis is the mimic of older adults: small, confetti-like white macules, usually two to five millimeters, scattered on chronically sun-exposed shins and forearms. It reflects a localized age and photodamage-related drop in melanocyte number and activity. The lesions are stable, tiny, and multiple, whereas vitiligo macules typically enlarge and coalesce. IGH is cosmetically bothersome but medically benign, and it does not respond to vitiligo therapies in any meaningful way.

Why does the diagnosis change management so much? Because vitiligo treatment is fundamentally immunologic. Topical corticosteroids, topical calcineurin inhibitors, narrowband UVB phototherapy, and the newer topical JAK inhibitor class all work by dampening the interferon gamma and CXCL10 signaling axis that drives melanocyte killing, then coaxing melanocyte stem cells out of hair follicles to repigment the skin. None of that logic applies to a yeast infection or age-related melanocyte dropout. Conversely, treating early vitiligo as if it were pityriasis alba wastes the period when disease activity is easiest to halt.

A few practical takeaways. First, sharp borders, absence of scale, and chalk-white Wood's lamp accentuation point toward vitiligo, particularly when patches appear around the eyes, mouth, fingertips, or genitals, or when hairs within the patch turn white. Second, scale almost always argues against vitiligo and toward an eczematous or fungal process. Third, history carries real diagnostic weight: prior rash or procedure suggests post-inflammatory change, sun-weathered shins in later life suggest IGH, and an atopic child suggests pityriasis alba. Finally, uncertainty is a legitimate reason for follow-up rather than guesswork. A repeat examination in eight to twelve weeks, with photographs for comparison, resolves most ambiguous cases, and a small punch biopsy with melanocyte staining settles the rest. White patches are common. True depigmentation is specific, and the tools to tell the difference are simpler than most patients expect.

Related reading: Not Every White Patch Is Vitiligo: How Clinicians Tell Four Common Look-Alikes Apart.